Parkinson's Disease:- "Drug research & development review in April 2022" by Dr Kevin McFarthing

This presentation gives an overview in April 2022 of research and clinical development for Parkinson’s, starting with an overview of trends. The 350+ active projects will be categorised by their position on the road to the patient and the objective, whether it is for symptom relief or disease modification. If you would like a link to the presentation slides, just email us at [email protected] a Ph.D. biochemist, Dr. Kevin McFarthing’s career included R&D leadership positions in life sciences research products with Amersham, diagnostics with Serono, and consumer healthcare with Reckitt Benckiser. He is joint editor of the Clinical Trial Highlights section of the Journal of Parkinson’s Disease and a member of the Research Committee of Cure Parkinson’s and is first author on a recent review of the clinical trial pipeline in Parkinson’s (https://content.iospress.com/articles... ). Kevin collates the Parkinson’s Hope List,  a database of potential therapies in research and clinical stages. Here is the link:-https://drive.google.com/file/d/1NeSy...He also chairs the Patient and Public Involvement and Engagement group for the Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease program. Kevin was diagnosed with Parkinson’s in 2012 at the age of 55.You can follow Kevin's social media on:-Twitter @InnovationFixer